JP7728264B2 - シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 - Google Patents

シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法

Info

Publication number
JP7728264B2
JP7728264B2 JP2022542294A JP2022542294A JP7728264B2 JP 7728264 B2 JP7728264 B2 JP 7728264B2 JP 2022542294 A JP2022542294 A JP 2022542294A JP 2022542294 A JP2022542294 A JP 2022542294A JP 7728264 B2 JP7728264 B2 JP 7728264B2
Authority
JP
Japan
Prior art keywords
compound
metabolism
agent
methyl
ox2r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510332A (ja
JP2023510332A5 (https=
Inventor
ファエッセル、ヘレーネ
ル、ホン
ヴェンカタクリシュナン、カールティック
チャン、リーミン
ワグナー、ジョン
ローゲ、マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2023510332A publication Critical patent/JP2023510332A/ja
Publication of JP2023510332A5 publication Critical patent/JP2023510332A5/ja
Application granted granted Critical
Publication of JP7728264B2 publication Critical patent/JP7728264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022542294A 2020-01-10 2021-01-07 シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 Active JP7728264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959514P 2020-01-10 2020-01-10
US62/959,514 2020-01-10
PCT/US2021/012447 WO2021142083A1 (en) 2020-01-10 2021-01-07 A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450

Publications (3)

Publication Number Publication Date
JP2023510332A JP2023510332A (ja) 2023-03-13
JP2023510332A5 JP2023510332A5 (https=) 2024-01-16
JP7728264B2 true JP7728264B2 (ja) 2025-08-22

Family

ID=74418549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542294A Active JP7728264B2 (ja) 2020-01-10 2021-01-07 シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法

Country Status (10)

Country Link
US (1) US12594269B2 (https=)
EP (1) EP4087534A1 (https=)
JP (1) JP7728264B2 (https=)
KR (1) KR20220127245A (https=)
CN (1) CN115226390B (https=)
AU (1) AU2021205892B2 (https=)
BR (1) BR112022013547A2 (https=)
CA (1) CA3167050A1 (https=)
MX (1) MX2022008392A (https=)
WO (1) WO2021142083A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AR130709A1 (es) 2022-10-07 2025-01-08 Kissei Pharmaceutical Compuesto de ciclopentano
KR20250085056A (ko) 2023-12-05 2025-06-12 안희태 국궁 과녁에서 영역 구분 센서의 구성 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
JP2019504098A (ja) 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
JP2019524777A (ja) 2016-08-04 2019-09-05 ギリアード サイエンシーズ， インコーポレイテッド がんの処置での使用のためのコビシスタット

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524104A (en) * 2000-09-08 2004-12-24 Pharmacia Italia S Exemestane as chemopreventing agent
BR112022004576A2 (pt) 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
CA3154321A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
JP2019504098A (ja) 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
JP2019524777A (ja) 2016-08-04 2019-09-05 ギリアード サイエンシーズ， インコーポレイテッド がんの処置での使用のためのコビシスタット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Allen CATO et al.，"The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin*"，Clinical Pharmacology & Therapeutics，1998年，Vol. 63, No. 4，p.414-421，DOI: 10.1016/S0009-9236(98)90036-4
Md Amin HOSSAIN et al.，"Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat"，Journal of Pharmacy and Pharmacology，2017年，Vol. 69, No. 12，p.1786-1793，DOI: 10.1111/jphp.12820

Also Published As

Publication number Publication date
WO2021142083A1 (en) 2021-07-15
BR112022013547A2 (pt) 2022-09-06
AU2021205892A1 (en) 2022-08-18
US12594269B2 (en) 2026-04-07
US20230029486A1 (en) 2023-02-02
AU2021205892B2 (en) 2026-04-23
CN115226390B (zh) 2026-03-20
JP2023510332A (ja) 2023-03-13
EP4087534A1 (en) 2022-11-16
KR20220127245A (ko) 2022-09-19
CA3167050A1 (en) 2021-07-15
CN115226390A (zh) 2022-10-21
MX2022008392A (es) 2022-08-08

Similar Documents

Publication Publication Date Title
JP7728264B2 (ja) シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法
Guttman-Yassky et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Busse et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
Xu et al. Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial
Donohue et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
Poyares et al. Chronic benzodiazepine usage and withdrawal in insomnia patients
US12465583B2 (en) Methods of treatment using an mTORC1 modulator
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
Mery et al. High false-positive rate of questionnaire-based restless legs syndrome diagnosis in multiple sclerosis
Lecendreux et al. Pharmacokinetics of pitolisant in children and adolescents with narcolepsy
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
JP2010534628A (ja) 神経変性障害を治療するためのネラメキサンの新規組合せ
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Jantikar et al. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study
RU2834228C1 (ru) Способ улучшения фармокинетики или повышения концентрации в плазме метил-3-((метилсульфонил)амино)-2-(((4-фенилциклогексил)окси)метил)пиперидин-1-карбоксилата или его соли с помощью ингибитора цитохрома p450
KR101961368B1 (ko) 수면 무호흡 치료용 술티암
Steinke et al. Polysomnographic findings in restless legs syndrome (RLS) patients with severe augmentation
von Leupoldt et al. The influence of corticosteroids on the perception of dyspnea in asthma
Krivosova et al. Therapeutic drug monitoring of venlafaxine and impact of age, gender, BMI, and diagnosis
US20260034109A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
Chen et al. Therapeutic Effects of Naloxone Combined with Edaravone on Elderly Patients with Acute Cerebral Infarction
Kong et al. Randomized, multicenter clinical study of tratinterol hydrochloride tablets for the treatment of bronchial asthma
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
Kaushanska et al. Therapy of patients with anxiety disorders and metabolic syndrome X
Kilty Spencer I. Danto, Negin Shojaee, Ravi Shankar P. Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan and

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250812

R150 Certificate of patent or registration of utility model

Ref document number: 7728264

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150